Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.51 |
| ▸ | PPARA | Q07869 | 11/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5904772 | 0.83 | FFAR1 (0.53) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL6035936 | 0.80 | PPARD (0.44) | PPARDPPARAPPARGRXRANR1H2 | |
| SCHEMBL6036203 | 0.78 | NR1H2 (0.43) | PPARDPPARAPPARGRXRANR1H2 | |
| SCHEMBL6143205 | 0.77 | PPARA (0.44) | PPARDPPARAPPARGRXRANR1H2 | |
| SCHEMBL5904742 | 0.76 | NOTUM (0.43) | — | |
| SCHEMBL6035564 | 0.74 | PLA2G4B (0.42) | PPARDPPARAPPARGRXRANR1H2 | |
| SCHEMBL5904648 | 0.74 | PPARA (0.40) | PPARDPPARAPPARGRXRANR1H2 | |
| SCHEMBL5904913 | 0.73 | PPARD (0.53) | PPARDPPARAPPARG | |
| SCHEMBL5904607 | 0.73 | FFAR1 (0.46) | PPARDPPARAPPARGFFAR1FFAR4 | |
| SCHEMBL1010424 | 0.73 | MAOB (0.64) | PPARDPPARAPPARGRXRAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241157-A1 | Heterocyclic ppar modulators | ELI LILLY AND COMPANY | 2006-10-26 | — | — | US | disclosed |
| EP-1585733-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004063166-A1 | HETEROCYCLIC PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241157-A1 | Heterocyclic ppar modulators | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.